Registration Open: Paying for Cures Workshop March 10 at MITSurvey the financial challenges of sustaining new cell and gene therapies, assess adoption barriers, and anticipate coming changes in practice and … Read More
Impact of FDA Guidelines on Communication between Developers and Payers on Metrics in Performance-Based Agreements
The FDA regulates communications from pharmaceutical developers to ensure that statements about products are appropriately supported by evidence. In this Research Brief, we explore the possible impacts of these regulations … Read More
Payer Perspectives on Reimbursement of One-Time High-Cost Durable Therapies
Jane F. Barlow, Matt W. Courtney, and Mark Trusheim of the FoCUS Project contributed the article to PharmExec.com, published January 9, 2020. The reimbursement of emerging durable and potentially curative … Read More
Payer Perspectives on Reimbursement of One-Time High-Cost Durable Therapies
Pharmaceutical Executive, January 9, 2020Matt W. Courtney, Jane F. Barlow, Mark Trusheim The reimbursement of emerging durable and potentially curative cell and gene therapies challenge U.S. payers due to their … Read More
Precision Financing challenges for solid tumor adoptive T-cell therapies
Durable gene and cell therapies represent a unique challenge to the US healthcare insurer/payer landscape, given the one-time treatment and associated high upfront cost but potentially durable outcomes. Previous research … Read More
Fourth LEAPS Design Lab at MIT focuses on challenges and potential value of Real World Data and Evidence in rheumatoid arthritis learning ecosystem
The LEAPS Project in the MIT Center for Biomedical Innovation’s NEWDIGS Initiative held its fourth Design Lab on December 11 and 12 at MIT. Innovators and leaders across the rheumatoid … Read More
LEAPS Monthly Recap: December 2019
Real World Data and Evidence in the rheumatoid arthritis learning ecosystem In the fourth LEAPS Design Lab, innovators and leaders across the rheumatoid arthritis (RA) research and patient care stakeholder … Read More
FoCUS Monthly Recap: December 2019
Year in FoCUS 7 research briefs, 4 white papers, and 2 peer-reviewed articles published; 40+ speaking engagements and conference appearances, 20+ appearances in media, 450+ attendees to Design Labs and … Read More
Making Cell and Gene Therapies Financially Accessible and Sustainable
CAMBRIDGE, Massachusetts, December 5—The Financing and Reimbursement of Cures in the US Consortium (FoCUS) launched the Paying for Cures Toolkit today. The free online resource helps payers, patient advocates, drug … Read More
Downstream Innovation Part I
There is a growing recognition of the importance of augmenting product- focused learning with disease-focused learning, incorporating the value of advances in real-world evidence (RWE). In LEAPS, we aim to … Read More